Personalized Medicine Experts Come Together to Discuss the Next Generation of Targeted Oncology

• 

...to understand how targeted oncology can be managed for success...

New York (PRWEB UK) 3 December 2013

Personalized medicine has become a buzzword in American pharma in recent years and no therapeutic area has benefitted from its clinical efficacy more than oncology, the USA’s most expensive disease area for providers and manufacturers alike. However, Paul Simms, Chairman at eyeforpharma, claims that many of the specific advantages of personalized therapeutics for the pharma industry remain untapped, due to uncertainty around how to manage huge quantities of clinical data and how to attain appropriate reimbursement on crucial diagnostic tests.

“Personalized medicine is something we hear about all the time, particularly in oncology,” stated Simms. “However, you’d be forgiven for thinking that this is an area that is now fully understood by all the stakeholders. In fact, our research has shown us time and time again that many manufacturers are held back from really extending these marvellous drugs to the right patients, due to confusion about the proper routes to access and reimbursement.”

In an attempt to establish a consensus on the ideal management of targeted therapy portfolios, eyeforpharma will be hosting a free webinar on Wednesday December 11th at 11.30 EST. “This is really just a question of clarity. We hope this webinar will enable all the stakeholders to understand how targeted oncology can be managed for success, and also to discuss what personalized medicine means to them and to their business,” Simms affirmed.

Industry Leaders Take Part in the Discussion

Laura Housman (Molecular Health, formerly Novartis) and Stan Skrzypczak (InVitae, ex-Genomic Health and Genentech), will share their years of experience in this field, as well as their incisive insights into the future, in the webinar next Wednesday.

Looking forward to the webinar, panelist Laura Housman, Senior Vice President and Chief Commercial Officer at Molecular Health, stated, “Personalized medicine is key to the future of cancer care in the USA, but uncertainty around reimbursement and how best to use clinical data can be a stumbling block for many in pharma. I hope through this webinar that some of my experiences in the field can highlight some of the best ways to take advantage of these next-generation, cutting-edge treatments.”

Over 500 attendees from across American oncology will listen in live to the webinar, during which time they will be invited to engage in discussion about the future of personalized oncology, and ask questions of the expert speakers.

Register for the webinar via the secure link below. The webinar will be held at 11.30am EST on Wednesday, December 11th. Those who cannot attend live will be sent a free recording after the webinar: https://www3.gotomeeting.com/register/293624206

About eyeforpharma:    

eyeforpharma is a hub for senior-level pharma executives, patient advocacy groups and other health experts to exchange ideas and stay up to date with shifting trends and practices within the pharmaceutical industry. We provide industry-focused commentary, events, reports, and other valuable expert-driven content. Our ultimate aim is to facilitate positive change through discussion and debate, enabling dialogue within the industry and driving the positive benefits that pharmaceuticals can offer.

Contact:
Aidan Brain
Head of Oncology | eyeforpharma
T: +44 (0) 207 375 7513
E: abrain (at) eyeforpharma (dot) com

PDF Print